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ABSTRACT
Human herpesvirus (HHSV) and human cytomegalovirus (HCMV) infections during pregnancy
are a major concern of public health because of the risk for severe sequelae for the fetuses and the
neonates and because primary infections, reinfections and reactivations can be asymptomatic. The
risk for neonatal herpes is mostly cngenital, while the risk for HCMV infection is either prenatal
or congenital. Screening exposed women has not brought definite solutions but is currently being
evaluated. Among pregnant women with active infection, evaluation of the fetus for contamination
and thus for the risk for severe immediate or long-term sequelae for neonates is the major goal.
Diagnostic tools are available, cell culture still being the gold standard, and polymerase chain
reaction (PCR) being currently evaluated for its contribution to diagnosis of active infection. Con-
sensus for screening pregnant women as well as achievement of antiviral vaccines are the most
urgent intervention strategies to develop in the near future. Infect. Dis. Obstet. Gynecol. 5:133-141,
1997. (C) 1997 Wilcy-Liss, Inc.
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HSV and HCMV, members of the Herpesv-
iridae family, are causal agents of ubiquitous
infections. Although mostly asymptomatic, their
common feature is to dangerously affect childbirth
if infection occurs during pregnancy or delivery.
For both viruses, primary infection during preg-
nancy is a major public health issue because of
severe risks for the child. After primary infection
the viruses never leave the host and enter into a
latency or persistence state which is the key to the
immunopathogenesis of the infection.
Prevention and treatments are available, but for
both infections, screening exposed women is con-
troversial because the risk for neonatal contamina-
tion is not clearly estimated.
We will revew the pathogenesis of both viruses
for pregnant women and expose intervention strat-
egies. Herpesviridae family, composed of more
than 100 members, is divided in 3 subfamilies,
13- and y-herpesvirinae, according to their biologi-
cal criteria, like cycle duration, latency or persis-
tence in the host, and their oncogenic properties.
Eight herpesviruses infect the human. Herpes-
simplex virus type 1 (HSV1) and type 2 (HSV2) are
responsible for labial and genital herpes, respec-
tively, and varicella and zona virus (VZV) are
Herpesvirinae. Human cytomegalovirus (HCMV),
HHV type 6 and HHV type 7 are 13-herpes virinae,
marked by their opportunistic pathogenesis. Ep-
stein-Barr virus (EBV) agent of the infectious
mononucleosis, linked to Burkitt lymphoma and
nasopharynx carcinoma, and HSV type 8 found in
Kaposi disease lesions, are y-herpesvirinae marked
by their oncogenic properties.
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GENERAL PROPERTIES OF HSV AND CMV
These two viruses share the general morphology of
the herpesviruses. Their double stranded linear
DNA is surrounded by an icosaedric capside form-
ing the nucleocapside; enclosed in an envelope
formed by a double layer of cellular phopholipids
and viral glycoproteins, are the nucleocapside and
the tegument, amorphous material containing pro-
teins without DNA. Host cell penetration by the
two viruses occurs through still unknown cellular
receptors. The virus binds by glycoprotein C (gC)
or secondarily by glycoprotein B (gB) to cellular
heparin sulfate type proteoglycans, z The viral rep-
lication takes place in 3 phases.
3
The very early phase corresponds to the imme-
diate early proteins (IE) synthesis, transactivated
by the tegument proteins.4 The early phase, where
the early (E) proteins are synthetised after transac-
tivation by the IE proteins, opens to DNA synthe-
sis. Then structural protein synthesis corresponds
to the late phase.
HHSV and HCMV genomes are constituted of a
linear double stranded DNA of 155 Kbp and 240
Kbp respectively,s organized in two single units, a
long one (UL) and a short one (Us) framed by
repeated reverse sequences (TRL and IRL for UL,
IRS and TRS for Us).6 The differential orientation
of those single units allows 4 isomeres for each
genome. 7 These genomes contain 100 opening
reading frame (ORF) for HHSV and more than 200
ORF for HCMV. HSV1 and HSV2 share more than
50% of nucleotidic sequence homology.
8
The leader of the subfamily of cx Herpesviridae,
HHSV1 is characterized by a broad host spectrum
in vitro, narrow in vivo, a short viral cycle, latency
and reactivation properties, a viral thymidine ki-
nase mediated neurovirulence9 and a gD and gB
mediated neuroinvasion.1
The leader of the subfamily of [3 Herpesviridae,
HCMV is characterized by a narrow host spectrum
in vitro, broad in vivo, a long viral cycle (abortive
dense corpuscles synthesis or permissive virion
synthesis), and properties of persistence and reac-
tivation.
PATHoGENESIS
Epidemiology
Humans are the only natural reservoir of HHSV
and HCMV.
Infection seroprevalence in adults is 70% for
HHSV1 and 10 to 60% for HHSV211 depending on
socioeconomic status and sexual habits.
Contamination occurs mostly by contact with
oropharyngeal or genital secretions. HCMV sero-
prevalence varies with socioeconomic status, age
and sex (women are more often infected than
men). In France, the HCMV seropositivity rate is
around 50% by the age of 35.12,13,14,15 The rate
peaks at 80% at the age of 3 in developing coun-
tries. 16,17,18 Transmission can occur by blood, tears,
maternal milk, semen, genital secretions, urine, sa-
liva, and by transplacental passage during the vire-
mia which accompanies the active infection, either
primary infection (p.i.), reinfection or reactivation.
Clinical Features
HHSV1-2 p.i. is most of the time not apparent.
HHSV1 p.i. symptoms are variable. Gingivostoma-
titis with dysphagia, fever and cervical adeno’fds, or
kerato-conjunctivitis, or encephalitis, can be found.
HHSV1 can also infect the genital tract. HHSV2
p.i. can be responsible for genital vesicular lesions
with fever and inguinal adenoids, and for neonatal
herpes (NNH). Rare cases of fulminating hepatitis
have been described in pregnant women during p.i.
Clinical forms of reactivation are labial herpes for
HHSV1 and genital herpes or neonatal herpes for
HHSV2. Those reactivation forms are localized or
disseminated according to the immunocompetency
or the immunodepression of the host.
HCMV p.i. may not be apparent. The virus is
responsible for 8% of the mononucleotic syn-
droms 19 and for a condition of which importance is
directly correlated to the level and type of the host
immunodepression: HCMV is the infectious agent
responsible for opportunistic infections of viral
prognosis, either with the p.i. (60% incidence in
the transplanted) or with reinfections (40%) or re-
activations (20%). Moreover, the frequency of
those pathologies varies with the type of immuno-
depression. 20% of bone marrow transplants de-
velop a very severe interstitial pneumopathy (80%
of all HCMV diseases in this population) versus
hardly 1% of better prognosis, in the AIDS popu-
lation. Conversely, 10 to 15% of HIV seropositives
at AIDS phase with CD4+<100/mm3 develop a ret-
initis (80% of all HCMV diseases in this popula-
tion) and more than 5% an ulcerative colitis, those
two conditions being very rare in the bone marrow
134 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYPATHOGENESIS OF HSVAND CMV INFECTIONS IN PREGNANCY ASKIENAZY-ELBHAR AND SIFER
transplant population. HCMV is also responsible
for encephalitis, hepatitis, leucopenia in those im-
munodepressed populations, as well as congenital
infection of variable severeness. Some Guillain-
Barr6 syndromes have been described, especially
in pregnant women.
Latency
The site of HHSV latency has been located by in
situ hybridization (ISH). The viral gcnome has
been found in neuronal cells of neurosensitive ad-
enoids,z Molecular studies have demonstrated the
existence of latency associated transcripts (LAT),
viral transcription products present only during la-
tency, el This anatomically well defined latency ex-
plains the clinical identity of recurrent episodes
caused by an acute stress.
The location ofHCMV latency is still unknown,
and absolute evidence of latency has not been
brought yet for this virus since no cellular line has
allowed to obtain the virus in latency without rep-
lication.
Nevertheless we know that it persists for the
lifetime of the host.zz ISH assays have shown its
presence in monocytes, epithelial and endothelial
cells of different organs of healthy individuals,z3
Virus and host maintain a balance status in such a
way that the cell cannot get rid of the virus but
prevents virus replication. Animal models have
shown that replication and dissemination rate dur-
ing primary infection determine the probability of
latency in a given organ, and that those factors are
more important in neonatal than in adult infec-
tion.z4 It is likely that HCMV DNA is not inte-
grated in the cell genome and that the virus repli-
cation is regulated by cellular transcription factors.
HCMV is coated with 132 microglobulin chains
which hide the epitopes recognized by neutralizing
antibodies. There is a low rate of replication rather
than a latent infection for this virus.
HCMV reactivation occurs after an immunode-
pressive state, either iatrogenic (graft, chemo-
therapy) or natural (AIDS, pregnancy, stress), and
the associated viremia explains the clinical features
of this reactivation.
IMMUNOPATHOLOGY
HHSVI-2
Antibodies are responsible for protection from re-
infection and for neutralisation of the neuroinva-
sion in adults.2s That is why herpetic encephalitis
is not more frequent in immunodepressed or in
immunocompromised patients. However, the
transplacentae transfer of humoral immunity does
not always protect the newborn from perinatal in-
fection. CD4+ lymphocytes are responsible of virus
elimination at the periphery,z6 Thus, HHSV1-2 in-
fections are easily disseminated in immunode-
pressed patients. Moreover, their ocular autoreac-
tivity gives its immunopathogenetic component to
the herpetic keratoconjunctivitis. They have no
role in herpetic encephalitis, where the demyelin-
ating inflammatory reaction is associated with the
virus multiplication. CD8+ lymphocytes control
the infection.
The neonate immune status is quite important
when congenital infection is concerned. There is a
relation between the maternal antibody transmis-
sion rate to the fetus and the development of
NNH. This factor, associated with a decreased T
cell response in the newborn, exposes the fetus to
NNH infection,z7
HCMV
Virus replication occurs only in differentiated cells
and is responsible for an increase of the global cel-
lular metabolism. HCMV is responsible for nonpro-
tecting antibody synthesis, which does not prevent
especially reinfection by another virus strain. The
infected cell decreases the synthesis of certain an-
tigens of the major histocompatibility complex
(MHC) class II, partly protecting itself from the
immune reaction of the host. An UL18 HCMV
gene, homologous to MHC class I molecules, can
efficiently inhibit infected cells lysis by natural
killer (NK) cells.28 Whether these homologues are
really expressed on the infected cell surface and
how they affect NK lysis must still be clarified.
Controlling HCMV infection depends on a specific
response of the cell mediated immune system.29
Most of the MHC restricted cytotoxic cells specifi-
cally recognize one single structural protein, phos-
phoprotein 65 (pp 65). The healing of a HCMV
infection is accompanied by an increase, of CD8+
lymphocytes and NK cells. Healthy patients sero-
positive for HCMV and seronegative patients dem-
onstrate an NK activity specific for the HCMV in-
fected cells, but this activity is stronger in HCMV
seropositives, which suggests its role in the virus-
host balance during viral persistence. A good NK
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response is positively associated with the lack of
symptoms in the congenitally infected child and
with the favorable evolution of the HCMV disease
in bone marrow transplants. HCMV immunopatho-
genesis is asserted by virus replication at the site of
clinical manifestations, but also by cellular destruc-
tion, and modification of cellular functions, espe-
cially cytokine production. Moreover, HCMV is
known to be immunodepressive: during the acute
phase of the HCMV mononucleotic syndrome,
there occurs susceptibility to secondary infections,
reversal of the CD4+ (helper)/CDS+ (supressive)
ratio, and autoantibody induction. In vitro lympho-
proliferation with specific or non specific HCMV
antigens, cytotoxic cell mediated activity, and pe-
ripheral blood leucocytes NK activity, are de-
creased,3 while differentiation cytokine and
growth factor production are stimulated. In fact,
interrelations between this virus and cytokine pro-
duction by infected cells modifying the immune
status of the considered tissue are extremely com-
plex, especially because the modifications vary
with the type of the infected cell.31’3z
NEONATAL HERPES
The frequency ofNNH is 1 to 5/10000 births with
HSV1 to 4 HSV2 cases. The disease is unex-
pected in two thirds of cases.33 Transmission oc-
curs by genital contact during delivery. The ab-
sence of viremia in immunocompetent individuals
excludes fetal contamination through the placenta.
However, in utero infections are reported, mostly
mediated by placentitis.
The mother exhibits no signs nor symptoms in
two thirds of cases.
In maternal genital p.i. at delivery, the risk for
NNH is 75% (no antibodies, virus +++). In mater-
nal genital recurrence at delivery, NNH risk is 3 to
5% (antibodies+/virus+).34 If there is a maternal or
paternal genital history, the risk is 10%. As for any
female patient, the risk for NNH is 1% (0.1 to 1%
are asymptomatic excretors).5 The diagnosis is
made by sampling the vesicles at the infected sites
and culturing them on human fibroblasts. The cy-
topathic effect (CPE) is read within 48 hours. Cy-
todiagnostic tests and ELISA can also be used.
In case of a previous history of genital herpes,
the diagnosis of an asymptomatic excretion at the
cervix is made by cell culture or direct immunoflu-
orescence assay (DIFA). Gent amplification with
PCR is currently being evaluated for this indica-
tion.36 This very sensitive technique is of contro-
versial benefit because it does not differentiate la-
tency from active infection, which is essential for
NNH risk evaluation.
For the child, asymptomatic forms are excep-
tional. There are severe disseminated forms (icte-
ria, purpura, hepatosplenomegaly, respiratory signs
associated or not associated with vesiculous le-
sions), severe forms localized to the central nervous
system (CNS) resulting in encephalitis. Those two
forms are of redoubtable prognosis.
Benign forms, localized in skin or mouth, are of
better prognosis.7 The embryopathy resulting
from early maternal fetal transmission is excep-
tional. NNH mortality or irreversible sequelae are
50% without treatment.8
A quick diagnosis of vesicular lesions can be
made by DIFA, ELISA or electron microscopy. Vi-
rus can be isolated by cell culture of vesicles, tears,
blood, pharyngal samples, urine, and, less con-
stantly, cerebrospinal fluid, blood and biopsies.
9
Treatment as a pediatric emergency should be
started as soon as NNH is clinically suspected. In-
traveinous acyclovir (ACV), 10-15 mg/kg 3 times a
day for 10 to 14 days is the elective treatment for
NNH, thanks to which two thirds of the infected
children live without sequelae.
The primary prevention of NNH to avoid pre-
partum primary infection is sexual education of the
future parents (monogamy, condom use). Labial
herpes bearers should refrain from kissing neo-
nates.4o
Three strategies are available in the prepartum
stage: cesarean section, iodine aseptization of the
genital tract, and ACV administration to the mother
and/or child. The choice of the strategy depends on
the patient’s situation towards genital herpes.
Four situations can be found (Table 1):
Situation 1 is a primary infection prepartum or in
the previous month: cesarean section is recom-
manded in the month before delivery, if possible,
with ACV administration to the neonate, especially
if the cesarean section has been delayed or per-
formed after rupture of membranes. The mother
can also be treated by ACV if she presents severe
clinical symptoms with maternal risk.
Situation 2 is recurrent herpes in the prepartum
or in the preceeding days: in this case, only the
cesarean section is recommended in the week be-
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TABLE I. The maternal genital herpes manifestations in relation to neonatal herpes
Frequency in
infected children’s Neonatal
Maternal situation mothers herpes risk Recommended proposition
Prepartum primary infection (or in the
preceeding month)
Recurrence in prepartum or in the
preceeding days
Maternal or paternal history of genital
herpes only
No herpes history no clinical manifestation
Rare ++++
75%
+
=2to5%
++
1/1000
++++ +/-
2/3 cases I/1000
Cesarean section
Discuss ACV
Cesarean section
Vaginal delivery after vaginal swab
and iodine aseptization, if
positive, discuss ACV
No intervention except avoid any STD
O. to I% of all pregnant women have an asymptomatic genital excretion of HHSV.
fore the expected term. An alternative prevention
strategy could be a long term ACV oral treatment of
pregnant women suffering frequent HHSV2 recur-
rent episodes.41
Situation 3 is a maternal or paternal history of
genital herpes. In this case, vaginal delivery is ad-
vised after genital iodine aseptization. Previously,
asymptomatic excretion of HHSV will be looked
for, and if positive, ACV will be given to the neo-
nate. In every situation with a risk for NNH, if
monitoring is used, electrodes must not be trans-
feted from the mother to the newborn to avoid
herpetic encephalitis.
In situation 4 where no herpes history nor clini-
cal manifestation is known, the only prevention is
to avoid any sexually transmitted infection during
pregnancy by primary prevention strategies.
HCMV CONGENITAL AND NEONATAL
INFECTION
HCMV is the primary cause of congenital viral in-
fections in the world, occuring in 0.4 to 2.3% of
neonates, 14a,4b ofwhom only 5-10% are symptom-
atic. Of the 90% asymptomatic cases, 10% will have
an abnormal development.42 But infection and
HCMV disease must be carefully differentiated.
In contrast to what happens with HHSV, clinical
manifestations are exceptional, corresponding for
1/30 to CID (cytomegalic inclusions disease), the
most severe case ofHCMV congenital infections.43
CID frequency is about 0.03%. Contamination oc-
curs through ascension from urogenital secretions
or mother’s viremia, into the placenta by blood leu-
kocytes.44 The virus reaches the fetus through the
placenta barrier and replicates in elected organs,
mostly kidneys,4s,46,47 and is excreted in the amni-
otic fluid.
The most severe cases result from a maternal
p.i. during pregnancy. Transmission rate to the fe-
tus varies from 30 to 50%.42,48,49,50 The risk for p.i.
during pregnancy varies from to 13% with the
studies and the countries,s,sz,s3 and increases with
the number of pregnancies (2.3% at first pregnancy
vs. 3.8% at the second).49 The presence of endo-
metritis or ovaritis implies the possible fetal infec-
tion by viral ascension or proximity. Asymptomatic
neonatal HCMV infections relate to viral reinfec-
tions and particularly reactivations during the third
trimester of pregnancy.More than 10% of pregnant
HCMV seropositive women excrete the virus
through uterine cervix during that period.
During secondary infections, after reactivation,
persistence of chronic infection or reinfection by an
other virus strain,s4,ss the maternal fetal transmis-
sion rate varies from 0.5% to 10%.48,49,56 The in-
fants are not protected from an acute infection by
maternal antibodies but from severe CNS disease.
Perinatal HCMV infection is very frequent. In a
population where 1% of children are viruric at
birth, 12 to 15% of the neonates are viruric at
month of age, due to the transmission by the ma-
ternal milksT,s8 or any other intimate contact. It is
asymptomatic in most cases, with 5 to 15% of in-
fraclinic in utero-aquired encephalitis leading to
mild neurotic sequelae or deafness,sg,6a’6b
In the mother, alarm signs are exceptionally pre-
sent in rare cases of maternal p.i. with fever, mono-
nucleotic syndrom, arthralgia, and moderate raise
of hepatic ALAT. This p.i. very rarely can result
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 137PATHOGENESIS OF HSVAND CMV INFECTIONS INPREGNANCY ASKIENAZY-ELBHAR AND SIFER
from a blood transfusion from a seropositive donor
to a seronegative receiver. It may occur that atten-
tion is drawn at ultrasound examination to an im-
portant fetal growth retardation, especially with in-
traskull calcifications.
In that case, p.i. diagnosis would be easily con-
firmed by virus detection in blood or urine by cul-
ture on human fibroblasts. Evidence of viral IE
proteins by immunocytochemistry allows to esti-
mate the viral titer in 48 hours. This. viremia or
viruria asserts the active infection without distinc-
tion of p.i. or secondary infection.
Determination of HCMV antigenemia in the
nuclei of circulating polymorphonuclear leukocytes
after cytocentrifugation by a monoclonal antibody
to pp6561 gives in 3 hours an answer with a good
sensitivity compared to cell culture. This semi-
quantitative antigenemia is of real diagnostic inter-
est in AIDS-associated HCMV diseases, but has
not yet been evaluated in pregnant women.
Circulating blood leukocytes PCR is currently
being evaluated for its contribution to the diagnosis
of active infection in pregnant women; but the
problem is the same as it is for HHSV1-2. Prelimi-
nary studies currently qualify and quantify HCMV
genome detection sites and detection proteins, and
try to correlate the active infection rate to resulting
clinical symptoms (hybrid capture, RT-PCR, se-
rum-PCR).
Indirect diagnosis of HCMV infections is diffi-
cult. In the presence of alarm signs, p.i. would be
easily confirmed by a seroconversion, which re-
quires two blood samples.
However, the high prevalence of HCMV in the
general population is an obstacle to the diffusion of
a serologic test for pregnant women. A single serum
can only tell if the patient is seropositive or nega-
tive at the time of the test. AntiCMV igM is lack-
ing in 11 to 30% of primary infections and thus is
not a certainty test for p.i., and when it is present,
it is not absolute evidence of active infection since
it can last for a year after primary infection, and 5 to
10% of secondary infections produce IgM. Labora-
tories have the legal obligation to keep sera frozen
at -20C for one year. This could allow the differ-
entiation of a p.i. from a reactivation in the pres-
ence of IgM if there were no IgM in the first se-
rum. Moreover, given the interactions between
herpetic infections and nonspecific reactivations of
the immune system (like antiCMV [3 clones non-
specific reactivation), serologic variations are not
always linked to a viral reactivation. IgG avidity
index is currently used in a few teams.6z
Evidence of an active HCMV infection in a
pregnant women does not allow us to conclude
there is a fetal infection. However, if an abnormal
fetal development is observed, it will be a strong
argument in favor of maternal fetal transmission.
In children, the exceptional CID offers a picture
of fetopathy (icteria, purpura, hepatomegaly, hy-
potrophy) along with cephalic signs (microcephaly,
microophtalmy, cerebral periventricular calcifica-
tions, chorioretinitis). The age of pregnancy during
maternal p.i. does not seem to interfere with the
fetus’ contamination risk.
The prognosis is very bad: 30% of CIDs are
lethal, 60% lead to irreversible sequelae, while only
10% lead to normal development.
As for the asymptomatic infection of 1% of all
neonates, it is responsible for heavy auditory long
term disorders (10 to 15% variable deafness) and
psychomotric retardation.
Neonatal infection diagnosis is seldom made
without CID. Prenatal diagnosis, when ultrasonog-
raphy is suspect, consists of amniocentesis from the
8th week or cordocentesis from the 17th week. Di-
rect virus detection is made by standard and/or
rapid cell culture 63 along with fetal IgM in cord
blood and nonspecific signs like fetal thrombope-
nia.64,65 A negative detection does not absolutely
eliminate the diagnosis because the lag time be-
tween maternal infection and viral excretion in the
fetus is not known.
In the newborn, virus isolation within the two
first weeks of life, especially in urine, gives defi-
nitely the evidence of in utero acquired infection.
Beyond this period, evidence of a HCMV viruria
does not allow us any longer to differentiate a con-
genital from a perinatal infection.66
IgM is also assayed at birth, in particular in cord
blood.
Two antiviral products are efficient against
HCMV: foscarnet and ganciclovir. They are par-
tially toxic, and they cannot change the acquired
lesions of CID, thus they cannot be used system-
atically to prevent late handicaps linked to congen-
ital asymptomatic infections.
Punctual trials are reported in the literature,
from intraveinous infusion of ganciclovir in the um-
bilical vein to intravenous treatment of the neo-
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nate. Those treatments have at best reduced the
viral titer without noticeable lessening of the symp-
toms. Ganciclovir is actually virostatic, not viroci-
dic, and stops virus multiplication without elimi-
nating it from the site of infection.67 When ganci-
clovir is stopped viral excretion starts again.6s The
benefit of the treatment could be to allow the CNS
to develop without bearing the consequences of
too heavy a viral inoculum. Therapeutic abortion is
very rarely indicated because of the lack of alarm
signs of the mother.
INTERVENTION STRATEGIES
Prevention of neonatal infection is almost impos-
sible. Of course, seropositive donor blood must not
be transfused to a seronegative pregnant woman.
Day-nursery hygiene must be observed,.since more
than 10% of the children living in this community
contract HCMV infection during their first year of
life.
However, the most frequent means of infection
among pregnant women can hardly be avoided:
contamination of a seronegative mother by an elder
child living in the community, which brings a
prime infection risk during the current pregnancy.
Screening of exposed women is currently being
evaluated in controlled studies. It is not systemati-
caly advised to date because of the inevitable ma-
ternal anxiety which cannot be compensated by
rational solutions if she contracts a primary infec-
tion during her pregnancy.
The risk for the fetus can not be evaluated be-
cause the duration of the HCMV incubation in
utero is not known, and the lag time between p.i.
and amniocentesis is uncertain; also, should the
risk of a second amniocentesis, if the first one is
negative, or of cordocentesis be taken? If amnio-
centesis is positive, 50% of the fetuses are not in-
fected.
So the only proposition should be therapeutic
abortion or long term pediatric follow up until cur-
rent studies can bring a consensus.69
The lack of an active vaccine against HCMV is
stressed. Vaccine completion has become a priority
of virologic fundamental research.7
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